Dendritic Spine and Synaptic Plasticity in Alzheimer’s Disease: A Focus on MicroRNA

Edwin Estefan Reza-Zaldivar1, Mercedes Azucena Hernández-Sápiens1, Benito Minjarez2, Ulises Gómez-Pinedo3, Victor Javier Sánchez-González4, Ana Laura Márquez-Aguirre1,5 and Alejandro Arturo Canales-Aguirre1,5*

1 Medical and Pharmaceutical Biotechnology Unit, CIATEJ, Guadalajara, Mexico, 2 University Center of Biological and Agricultural Sciences, University of Guadalajara, Guadalajara, Mexico, 3 Institute of Neurosciences, IDISSC, San Carlos Clinical Hospital, Madrid, Spain, 4 University Center of Los Altos, University of Guadalajara, Guadalajara, Mexico, 5 Preclinical Evaluation Unit, CIATEJ, Guadalajara, Mexico

Dendrites and dendritic spines are dynamic structures with pivotal roles in brain connectivity and have been recognized as the locus of long-term synaptic plasticity related to cognitive processes such as learning and memory. In neurodegenerative diseases, the spine dynamic morphology alteration, such as shape and spine density, affects functional characteristics leading to synaptic dysfunction and cognitive impairment. Recent evidence implicates dendritic spine dysfunction as a critical feature in the pathogenesis of dementia, particularly Alzheimer’s disease. The alteration of spine morphology and their loss is correlated with the cognitive decline in Alzheimer’s disease patients even in the absence of neuronal loss, however, the underlying mechanisms are poorly understood. Currently, the microRNAs have emerged as essential regulators of synaptic plasticity. The changes in neuronal microRNA expression that contribute to the modification of synaptic function through the modulation of dendritic spine morphology or by regulating the local protein translation to synaptic transmission are determinant for synapse formation and synaptic plasticity. Focusing on microRNA and its targets may provide insight into new therapeutic opportunities. In this review we summarize the experimental evidence of the role that the microRNA plays in dendritic spine remodeling and synaptic plasticity and its potential therapeutic approach in Alzheimer’s disease. Targeting synaptic deficits through the structural alteration of dendritic spines could form part of therapeutic strategies to improve synaptic plasticity and to ameliorate cognitive impairments in Alzheimer’s disease and other neurological diseases.

Keywords: Alzheimer’s disease, dendritic spine, spine remodeling, synaptic plasticity, microRNA

INTRODUCTION

Nowadays, synaptic plasticity is considered a mechanism in which the structure and composition of synapses change according to determined neural activity (Frere and Slutsky, 2018; Oby et al., 2019). Collectively, it has been established that synaptic plasticity is determined by morphological and functional modifications of synapses as a response to activities that induce variations in
the neuronal circuit, such as long-term potentiation (LTP) and long-term depression (LTD) (Ju and Zhou, 2018). At the cellular level, synaptic plasticity is mediated by structural changes (elongation, contraction, and shape changes), distribution, and function of the dendritic spines (Chidambaram et al., 2019).

Dendritic spines (DS) are small, highly dynamic protruding structures of the dendritic membrane where synapses occur (Chidambaram et al., 2019). These structures possess specialized subdomains with specific functions in synaptic transmission and plasticity, such as postsynaptic density (PSD), a complex composed by neurotransmitter receptors, mainly α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPAR) and N-methyl-D-aspartate receptors (NMDAR), scaffolding proteins, signal transduction molecules, ion channels, and cytoskeleton components that allow synaptic signal conversions into discrete biochemical responses that modify the spine morphology, receptor trafficking, and protein synthesis (Saneyoshi et al., 2010; González-Burgos, 2012). DS plasticity is crucial for the formation, maintenance and elimination of synapses. The assembly and remodeling of the neuronal circuit results from changes in density and properties of ionic channels and proteins that modulate the membrane conductance, as well as the cytoskeleton rearrangement (mainly actin filaments) that modifies the morphology and function of the DS (Fukazawa et al., 2003; Tada and Sheng, 2006; Fortin et al., 2012). As mentioned before, the electrophysiological mechanisms of LTP and LTD are effectors of DS plasticity due to the induction of large morphological and functional changes of DS. LTP is associated with a spine density increase, more stable spine heads and their components such as PSD (Segal, 2017). In contrast, LTD promotes DS contraction and density reduction (Hasegawa et al., 2015).

Currently, many neurological disorders are associated with aberrant changes in the neural connectivity and synaptic plasticity promoted by disruptions in DS shape, size, or density, suggesting that the DS dysfunction and the subsequent synaptic failure is a common and critical factor among these pathologies, particularly those involving deficits in information processing such as Alzheimer’s disease (AD) (Penzes et al., 2011; Dorostkar et al., 2015).

All structural and functional changes in DS involve gene regulatory networks controlling spine development, maturation and maintenance. In this context, microRNA (miRNA) have emerged as essential regulators of cellular processes to maintain an optimal synaptic plasticity during neuronal circuit formation and integration; a process that certainly implies the structural and functional modification of DS correlated with long-lasting changes in synaptic transmission (Hebert and De Strooper, 2009; Frere and Slutsky, 2018). This class of small non-coding RNA plays a significant role in the regulation of DS formation and stabilization during synaptic plasticity.

In summary, DS are considered a primary site of structural modification for synaptic plasticity. Alterations in these dynamic mechanisms are suggested to be directly involved in the development of neurological diseases like AD. Focusing on the miRNA, with its key roles in synaptic plasticity and controlling their expression, might be useful for cognitive capacity improvement. Thus, understanding the mechanisms involved in miRNA-mediated synaptic activity may provide insights into the development of new therapeutic strategies for neurological disorders such as AD.

### SYNAPTIC PLASTICITY IMPAIRMENT IN ALZHEIMER’S DISEASE

AD is the most prevalent neurodegenerative disease among the elderly. This disease is characterized by synaptic plasticity dysfunction and a progressive decline in cognitive capacities. The AD hallmarks are the extracellular deposition and aggregation of amyloid-beta (Aβ) into amyloid plaques, and intracellular accumulation of neurofibrillary tangles of hyperphosphorylated tau protein. These protein depositions promote a synaptic dysfunction including synapse and neuronal loss (van de Weijer et al., 2020).

Several studies have correlated the DS loss and subsequent synaptic dysfunction with cognitive decline during disease progression (Scheff et al., 2007; Spires-Jones et al., 2007; Zhou et al., 2019). Although the molecular mechanisms underlying the neuronal and synaptic loss have not been fully described, some reports demonstrate that the excessive accumulation of Aβ is one of the main contributing factors (detailed reviewed Marttinen et al., 2018). Evidence suggests that Aβ-induced excitotoxicity results in the modification of electrophysiological processes in LTP and LTD, promoting a massive loss of DS due to a balance disruption of spine formation and elimination near the amyloid plaques (Hsieh et al., 2006; Shankar et al., 2007; Li et al., 2009). It has been shown that possibly through cytoskeleton alterations mediated by cofilin, p38/MAPK and calcineurin signaling, the Aβ oligomers could partially block the NMDAR signaling, reducing synthetically evoked Ca²⁺ influx, triggering events associated with LTD, such as increased AMPAR endocytic removal (Hsieh et al., 2006; Selkoe, 2008). In addition, it was reported that Aβ-toxicity promotes the overactivation of PAR-1/MARK and LKB-1 kinases, whose overactivity causes loss of PSD-95 function, leading to synaptic depression, DS, and synapses loss (Zhang et al., 2007).

Furthermore, the accumulation of Aβ triggers an impairment in the regulation of glutamate levels inducing cytotoxicity and the modification of DS morphology and NMDAR composition (Marttinen et al., 2018). The glutamate induces a dual effect, the elongation and contraction of the same group of spines. This depends of the calcium influx magnitude and duration (Korkotian and Segal, 1999). Prolonged exposure to a high glutamate concentration induces a rapid loss and reduction of DS size (Segal, 1995) and the NMDAR desensitization, reducing the Ca²⁺ influx and LTD induction (Shankar et al., 2007). In contrast, a low glutamate concentration increases the length of the DS (Segal and Andersen, 2000).

In contrast to the data about Aβ roles in synaptic loss, there are few reports about tau implication in synaptic dysfunction. Despite the fact that spine dynamics is mainly regulated by microfilament and actin-associated proteins, it has been demonstrated that microtubules also regulate DS morphology and synapses (Brandt and Bakota, 2017).
hippocampal rat neurons, Aβ exposition induces elevation of intracellular Ca\(^{2+}\) levels and aberrant activation of kinases which phosphorylate tau at the KXGS motif, leading to destabilization of dendritic microtubules; the impaired dendritic transport and Ca\(^{2+}\) homeostasis lead to the decay of DS and synapses (Zempel and Mandelkow, 2012). Additional studies show that hyperphosphorylated tau mediates NMDAR-dependent toxicity via Src-family tyrosine kinase Fyn, a kinase necessary for NMDAR phosphorylation and interaction with PSD-95 to a subsequent NMDAR stabilization (Ittner et al., 2010). Tau hyperphosphorylation leads to the Tau/Fyn/PSD-95/NMDAR complex dissociation disrupting LTP-required synaptic potentiation (Frandemiche et al., 2014), reducing the number of functional DS (Tracy and Gan, 2018). In addition, hyperphosphorylated tau misorting into somatodendritic compartments promotes NMDAR overactivation, followed by Ca\(^{2+}\) influx and cytotoxicity (Li et al., 2018). However, further functional studies are necessary to determine the key cytoskeleton-associated components in the tau-induced toxicity.

These studies demonstrate the synaptic alterations mediated by Aβ and hyperphosphorylated tau protein toxicity. In this context, accumulation of Aβ and hyperphosphorylated tau could directly or indirectly promotes the weakening, inhibition of synapse strengthening and the further loss of synapses. Alterations in the DS cytoskeleton dynamics appear to accompany the synaptic alteration and memory in AD, in fact, such synaptic impairment seems to be a consequence of loss of DS and the impairment of LTD. Thus, understanding the molecular mechanism underlying AD synaptotoxicity may provide therapeutic targets for cognitive ability improvement.

### ROLES OF miRNA IN SYNAPTIC PLASTICITY

The miRNAs are a class of small non-coding RNAs of 18–22 nucleotides that act as posttranscriptional regulators of gene expression in virtually every cellular process. Their effects in

---

**TABLE 1** | Summary of studies implying miRNA in synaptic plasticity.

| miRNA     | Target effects | Major findings                                                                 | References                        |
|-----------|----------------|--------------------------------------------------------------------------------|-----------------------------------|
| miRNA-206 | BDNF           | Downregulation                                                                | Lee S. T. et al., 2012            |
| miRNA-574 | Nm1            | Downregulation                                                                | Li et al., 2015                   |
| miRNA-34a | SIRT1/STX-1A   | Downregulation                                                                | Fujino et al., 2011               |
| miRNA-30b | EphB2/SIRT1    | Downregulation                                                                | Sankar et al., 2019               |
| miRNA-125b| Cdk5/p35/GRIA2 | Downregulation                                                                | Song et al., 2019                 |
| miRNA-134 | Limk1/CREB     | Downregulation                                                                | Rajasethupathy et al., 2009       |
| miRNA-29a/b| Arpc3          | Downregulation                                                                | Lippi et al., 2011                |
| miRNA-135 | CPLX1/CPLX2    | Downregulation                                                                | Hu et al., 2014                   |
| miRNA-124 | CREB           | Downregulation                                                                | Rajasethupathy et al., 2009       |
| miRNA-485 | GRIA2/PSD-95   | Downregulation                                                                | Cohen et al., 2011                |
| miRNA-138 | LYPLA1         | Downregulation                                                                | Siegel et al., 2009               |
| miRNA-132 | ARHGAP32/MMP-9 | Downregulation                                                                | Wayman et al., 2008               |
| miRNA-188 | NFP2           | Downregulation                                                                | Lee K. et al., 2012               |
| miRNA-191 | TMCO2          | Downregulation                                                                | Hu et al., 2014                   |
| miRNA-218 | GRIA2          | Upregulation                                                                  | Rocchi et al., 2019               |

*Abbreviations in the table were illustrated in the text.*
gene silencing guide Argonaute proteins to target sites in the complementary 3′ untranslated region of mRNAs (Gebert and MacRae, 2019). In the brain, many miRNAs have been implicated in the neurogenic process such as the determination of neuronal fate, formation and stability of synapses, as well as synaptic plasticity modulation (Follert et al., 2014). Interestingly, miRNA expression increases under conditions which promote synaptic plasticity, for example LTD and LTP (Park and Tang, 2009).

Particularly in modulation of synaptic plasticity, miRNAs can regulate aspects such as dendritic outgrowth, spine morphology, and DS density (Table 1), contributing to the structural and functional organization of synapses as well as synaptic strength and excitability (Olde Loohuis et al., 2012; Ye et al., 2016).

miRNA ASSOCIATED TO AD-SYNAPTIC PLASTICITY IMPAIRMENT

Different studies on AD revealed that altered miRNAs levels including the miRNA-101, miRNA-106, miRNA124, miRNA-9, miRNA-134, miRNA-132, miRNA-29a/b, miRNA-107, miRNA-206, and miRNA-146 (Candido et al., 2019), play a critical role in the phenotypic changes during disease progression, particularly the production of Aβ, hyperphosphorylated tau, BACE1, and gamma-secretase expression and ADAM-secretase inhibition (detailed reviewed in Reddy et al., 2017). Here, we reviewed those particularly involved in synaptic and DS plasticity. For instance, the miRNA-206 overexpression in Tg2576 mice that negatively regulates BDNF (UniProt code P23560), a neurotrophin with the ability to modulate synaptic function, enhances neurogenesis, and facilitates LTP. This overexpression contributes to AD pathology through BDNF downregulation. In contrast, miRNA-206 inhibition enhances synaptophysin expression and increases the hippocampal neurogenesis (Lee S. T. et al., 2012). In APP/PS1 mice, the hippocampal synaptic loss is accompanied by miRNA-574 overexpression, whose effects are mediated probably by Nrn1 (UniProt code Q9NP7D) inhibition (Li et al., 2015). Nrn1 is a neurotrophic factor that promotes neuritogenesis, spine stabilization, and formation and maturation of synapses (Fujino et al., 2011). Besides the synaptic loss, miRNA-574 overexpression is correlated with the cognitive impairment in this model.

In a miRNA-34a overexpression transgenic mice, the appearance of cognitive decline and AD neuropathology are sooner than in a single Tg-AD mice, 3xTg-AD mice, and even 5xTg-AD mice (Sarkar et al., 2019). This study showed that SIRT1 (UniProt code Q96EB6) is the main target of miRNA-34a. SIRT1 is necessary for cognitive function and synaptic plasticity-dependent of CREB (UniProt code P16220) and BDNF (Gao et al., 2010). SIRT1 inhibition by miRNA-34a increases tau phosphorylation levels (Sarkar et al., 2019). Additionally, miRNA-34a overexpression alters the spine morphology and function by targeting the synaptic proteins Syt-1 (UniProt code P21579) and Stx-1A (UniProt code Q16623) (Agostini et al., 2011). In a 5xFAD APP transgenic mice and AD patients' brains, it was evidenced that an elevated expression of miRNA-30b significantly downregulates ephB2 (UniProt code P29323), SIRT1, and GRIA2 (Uniprot code P42262) – molecules necessary for maintaining synaptic integrity. Overexpression of miRNA-30b in the hippocampus impairs basal synaptic transmission, LTP, learning, and memory, as well as reduction of DS density (Song et al., 2019).

In an in vitro neuron culture, miRNA-125b overexpression leads to elevated Cdk5/p35 (UniProt code Q15078) expression and MAPK signaling, which results in Tau hyperphosphorylation at multiple sites. Also, miRNA-125b injection into the hippocampus impairs learning in mice (Banhaf-Strathmann et al., 2014).

Despite the fact that the precise pathological mechanisms underlying synaptic impairment remain unclear, the evidence suggests that dysregulation of miRNA in AD is closely associated with the negative regulation of synaptic capacity and cognitive decline. The dysregulation of miRNA in AD and its implications to cognitive deficit requires further studies.

REGULATION DENDRITIC SPINES PLASTICITY BY miRNA

Currently, there are few miRNAs described with a specific function in the regulation of spinogenesis and DS morphology (Figure 1). There are miRNAs with negative effects in the DS plasticity, for example, the miRNA-134, whose effect is mediated by Limk1 (UniProt code P53667) inhibition, a kinase that promotes spine actin polymerization by inhibiting ADF/cofilin. Therefore, the overexpression of miRNA-134 causes a marked DS density reduction resulting in a weak synaptic transmission (Schratt et al., 2006). Another miRNA with a negative cytoskeleton regulation is the miRNA-29a/b cluster; miRNA-29a/b expression regulates the DS morphology through Arpc3 (UniProt code O15145), a subunit of the actin ARP2/3 nucleation complex, reducing the probability of actin branch formation, a fundamental step in DS maturation (Lippi et al., 2011). miRNA-125b negatively regulates synaptic plasticity by inhibition of GRIN2A (UniProt code Q12879) and possibly EphA4 (UniProt code P54764); miRNA-125b overexpression induces formation of long and narrow DS filopodia-like, with a subsequently synaptic transmission weakening. There is a positive correlation between the miRNA-125b expression and the cognition decline (Edbauer et al., 2010).

Moreover, it has been reported that miRNAs control the DS and synapse stabilization. In an LTD study, it was reported that miRNA-135 negatively regulates CPLX1 (UniProt code P14810) and CPLX2 (UniProt code Q6PUV4), complexins implicated in the late step of vesicles exocytosis, which inhibition reduces the postsynaptic exocytosis of AMPA receptors leading to DS retraction (Hu et al., 2014). The miRNA-124 and miRNA-134 have been associated with synaptic plasticity modification by CREB regulation. The reduction of miRNA-124 expression enhances synaptic plasticity allowing the increase of CREB-dependent transcription (Rajaseethapathy et al., 2009). In the same way, miRNA-134 inhibition increases the production of BDNF by enhancing CREB activity (Gao et al., 2010). In addition, overexpression of miRNA-485 reduces DS density by GRIA2.
inhibition (UniProt code P42262) along PSD-95 (DLG4, UniProt code P78352) clustering; however, the mechanism by which this miRNA produces the density reduction is unknown (Cohen et al., 2011). In another study, it was reported that miRNA-138 regulates DS growth by LYPLA1 inhibition (UniProt code O75608), an enzyme with a function in protein depalmitoylation. The increase in palmitoylation of the cysteine residues and their subsequent membrane location triggers a high RhoA signaling, which induces DS shrinkage with a reducing synaptic activity (Siegel et al., 2009).

On the other hand, there are miRNAs with a positive regulation on DS plasticity. For instance, miRNA-132, the best-studied miRNA in the synaptic plasticity context induces the formation of spines inhibiting ARHGAP32 (UniProt code A7KAX9), a member of the Rho GTPase family (Wayman et al., 2008). Subsequently, it was reported that miRNA-132 inhibits the extrasynaptic MMP-9 (UniProt code P14780), whose overexpression promotes the formation of long, thin and immature DS; MMP-9 inhibition by miRNA-132 promotes DS head widening, a process involved in the potentiation of synaptic plasticity (Jasinska et al., 2016). Unlike as miRNA-124 and miRNA-134, miRNA-132 is required for CREB-mediated dendritic growth and spine formation, particularly the formation of mushroom spines and their subsequent maturation (Mellios et al., 2011). In a recent study, the upregulation of miRNA-132 by an enriched environment enhanced hippocampal synaptic plasticity, and prevented the LTP impairments induced by Aβ oligomers (Wei et al., 2020). Interestingly, the miRNA-132 overexpression in transgenic models, promotes an excessive DS growth (Hansen et al., 2013), limiting the proper functioning of neurons and inducing alterations of LTP and LTD (Scott et al., 2012).
In another study, it was described that miRNA-188 overexpression selectively inhibits NRP2 (UniProt code O60462), a semaphorin 3F receptor that induces neuronal growth cones repression, and is capable of disturbing the DS and synaptic structure leading to a significant decrease of DS density. Therefore, when miRNA-188 inhibits NRP2, the reduction in DS density is reverted (Lee K. et al., 2012). In LTD, miRNA-191 decreased the elimination and contraction of DS by inhibiting TMOD2 (UniProt code Q8NZR1), a protein that promotes the depolymerization of actin (Hu et al., 2014). The miRNA-218 enhances the expression of GRIA2 subunit of AMPAR, increasing the amplitude of synaptic currents (Rocchi et al., 2019) and the formation of thin DS (Torres-Berrio et al., 2019).

Together, all this evidence shows the miRNAs regulatory roles in DS morphogenesis, both in pathological and physiological conditions. Although further research is necessary to clarify the crosstalk between these molecules and their targets, understanding all the miRNA-related effects could be used to develop protective strategies against the functional and behavioral alterations induced by chronic stress conditions such as AD.

PROTEIN-PROTEIN INTERACTION NETWORKS AND FUNCTIONAL ENRICHMENT ANALYSIS

We performed a literature search in databases including Web of Science, PubMed and Google Scholar. The keywords chosen included “microRNA,” “Alzheimer’s Disease” with either “dendritic spine,” “synapse,” and “synaptic plasticity.” With the information extracted from the selected articles we generated a figure composed of a network of known and predicted protein-protein interactions using the STRING program (Szklarczyk et al., 2017) and reported miRNAs targets. The interactome network represented in Figure 1, describes a minimum required interaction score of 0.70 (high confidence) between proteins, highlighting in red the biological processes of regulation of cytoskeleton organization with the interaction between 16 members with a false discovery rate (FDR) of 1.89e−14. In blue is shown the regulation of neuron projection development with 13 members and an FDR of 4.59e−11. In green, is shown the protein binding as the main molecular function with 33 members and an FDR of 4.23e−10. In pink is shown all the 22 members which are part of the neuron projection and in yellow the 19 members localized/involved in the synapse with an FDR of 5.91e−16 and 6.39e−15, respectively. Finally, in dark green, are shown the 14 members which are regulated by miRNA implicated in synaptic plasticity with an FDR of 1.14e−20.

Here, we show that most of the reported miRNAs affect the protein binding property (green nodes) of their targets. This promotes incapacity in assembly complexes required for cytoskeleton modification (red nodes) as reported by Lippi et al., 2011, or in the case of GRIN2A, the interaction with DLG4 to NMDAR stabilization and LTP induction, a process associated with the formation and maturation of mushroom DS (Mellios et al., 2011). In the synapse (yellow node), miRNAs such as miRNA-30b, miRNA-125b, and miRNA-485 interfere with the activation of NMDAR and AMPAR by inhibiting glutamate receptor subunits or impairment of AMPAR, and NMDR exocytosis. Impairments in AMPAR and NMDAR stabilization and activation results in unfavorable changes in DS morphology that blocks LTP activation. Interestingly, most of the miRNAs induce changes in the synaptic capacity by destabilization of the DS cytoskeleton, and although it was not discussed here, the inhibition of different proteins by particular miRNA could simultaneously impact other components involved in plasticity (Neighborhood and experiments stripes). In contrast, overexpression of miRNA-132, miRNA-188, and miRNA-191 could enhance DS formation and maturation by inhibiting enzymes with actin depolymerization functions and neuronal growth cone repressions.

This predicted protein-protein interactions network emphasizes the critical role of miRNA in the synaptic plasticity of normal neural function. This kind of bioinformatic analysis allows for the identification of potential pathways linking the pathological synaptic activity to miRNA function and in this way, the design of therapeutics strategies.

Nowadays, with sophisticated tools for miRNA expression screening and target prediction we can identify key miRNAs in certain processes (e.g., DS cytoskeleton destabilization). However, these computational predictions have a low accuracy rate and could include false-positive non-functional targets and miss some true-positive targets. Therefore, it is essential to validate these predictions with in vivo and in vitro experiments, and thus, determine their suitability for therapeutic strategies. Despite complications around miRNA therapeutics, such as a poor understanding of the stoichiometric relationship between a specific miRNA and the copy of its targets, the ubiquitous miRNA nature, miRNA site-specificity, and off-target effects (Bonneau et al., 2019; Bajan and Hutvagner, 2020), miRNA technologies have been applied successfully as an experimental therapy in basic research, as demonstrated by all the studies reviewed.

CONCLUSION AND PERSPECTIVES

Synaptic dysfunction is a common and critical factor among many neurological disorders. Synaptic failure as a consequence of DS loss has been associated with the cognitive impairment in pathologies such as AD. In this context, it has already demonstrated that miRNAs play essential roles in the synaptic regulation and neural survival, thus influencing cognitive function in both physiological and pathological conditions.

Even though the disease progression interference through miRNA regulation seems to be a promising therapeutic strategy, it is necessary a deep insight into the miRNA signaling to understand the mechanisms that rule processing, stability, and activity of these molecules in both physiological and pathological conditions. Furthermore, the identification of signaling pathways that strengthen synaptic transmission and synaptogenesis is required to design strategies for rational synaptic plasticity structural and functional modification. Also, it is crucial to
determine the effects of synaptic modification in existing neural circuits before the development of miRNA treatment strategies.

Combining high-throughput identification and functional assays to identify miRNA activity with the application of different technologies such as patient-specific IPSC-derived neuron cultures for neurodegenerative disease modeling, plus next-generation sequencing, represents an excellent experimental system to evaluate the relative expression, function, and target transcripts of particular miRNAs at the cellular level. Moreover, with the development of advanced techniques like two-photon laser scanning microscopy combined with glutamate caging, and super-resolution spine imaging and humanized cell models, we could determine the precise neuroanatomical changes of DS in several conditions and understand the synaptic connectivity and plasticity processes, allowing for the development of new therapeutic strategies for AD and other neurological disorder treatments.

REFERENCES

Agostini, M., Tucci, P., Steinert, J. R., Shalom-Feuerstein, R., Rouleau, M., Aberdam, D., et al. (2011). microRNA-34a regulates neurite outgrowth, spinal morphology, and function. Proc. Natl. Acad. Sci. U.S.A. 108, 21099–21104. doi: 10.1073/pnas.1112063108

Bajan, S., and Hutvagner, G. (2020). RNA-based therapeutics: from antisense oligonucleotides to miRNAs. Cells 9:139. doi: 10.3390/cells9010137

Banzhaf-Strathmann, I., Benito, E., May, S., Arzheimer, T., Tahirovic, S., Kretschmar, H., et al. (2014). MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. EMBO J. 33, 1667–1680. doi: 10.15252/embj.201385756

Bonneau, E., Neveu, B., Kostantin, E., Tsongalis, G. J., and De Guire, V. (2019). How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. EJIFCC 30, 114–127.

Brandt, R., and Bakota, L. (2017). Microtubule dynamics and the neurodegenerative triad of Alzheimer’s disease: the hidden connection. J. Neurochem. 143, 409–417. doi: 10.1111/jnc.14011

Candido, S., Lupo, G., Pennisi, M., Basile, M. S., Anfuso, C. D., Petralia, M. C., Banzhaf-Strathmann, J., Benito, E., May, S., Arzheimer, T., Tahirovic, B., Brandt, R., and Bakota, L. (2017). Microtubule dynamics and the intermediary role for dendritic spines. Prog. Neuropsychopharmac. Biol. Psychiatry 92, 161–193. doi: 10.1016/j.pnpbp.2019.01.005

Cohen, J. E., Lee, P. R., Chen, S., Li, W., and Fields, R. D. (2011). MicroRNA regulation of homeostatic synaptic plasticity. Proc. Natl. Acad. Sci. U.S.A. 108, 11650–11655. doi: 10.1073/pnas.1017576108

Dziembowska, M. (2016). miR-132 regulates dendritic spine structure by direct targeting of matrix metalloproteinase 9 mRNA. Mol. Neurobiol. 53, 4701–4712.

Follert, P., Cremer, H., and Beclin, C. (2014). MicroRNAs in brain development and function: a matter of flexibility and stability. Front. Mol. Neurosci. 7:15. doi: 10.3389/fnmol.2014.00005

Fortin, D. A., Srivastava, T., and Soderling, T. R. (2012). Structural modulation of dendritic spines during synaptic plasticity. Neuroncistics 18, 326–341. doi: 10.1177/1073858811410206

Franchediche, M., L., Seo, S., Rush, T., Borel, E., Elie, A., Arnal, I., et al. (2014). Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J. Neurosci. 34, 6084–6097. doi: 10.1523/JNEUROSCI.4261-13.2014

Ferre, S., and Slutsky, I. (2018). Alzheimer’s Disease: from firing instability to homeostasis network collapse. Neuron 97, 32–58. doi: 10.1016/j.neuron.2017.11.028

Fujino, T., Leslie, J. H., Eavri, R., Chen, J. L., Lin, W. C., Flanders, G. H., et al. (2011). CPG15 regulates synapse stability in the developing and adult brain. Genes Dev. 25, 2674–2685. doi: 10.1101/gad.176172.111

Fukazawa, Y., Saitoh, Y., Ozawa, F., Ohta, Y., Mizuno, K., and Inokuchi, K. (2003). Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance in vivo. Neuron 38, 447–460. doi: 10.1016/s0896-6273(03)00206-x

Gao, J., Wang, W. Y., Mao, Y. W., Graff, J., Guan, J. S., Pan, L., et al. (2010). A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 466, 1105–1109. doi: 10.1038/nature09271

Gebert, L. F. R., and MacRae, I. J. (2019). Regulation of microRNA function in animals. Nat. Rev. Mol. Cell Biol. 20, 21–37. doi: 10.1038/s41580-018-0045-47

González-Burgos, I. (2012). From synaptic transmission to cognition: an intermediary role for dendritic spines. Brain Cogn. 80, 177–183. doi: 10.1016/j.bandc.2012.03.002

Hansen, K. F., Karelina, K., Sakamoto, K., Wayman, G. A., Impye, S., and Obrietan, K. (2013). microRNA-132: a dynamic regulator of cognitive capacity. Brain Struct. Funct. 218, 817–831. doi: 10.1007/s00429-012-0431-434

Hasegawa, S., Sakuragi, S., Tomina-ga-Yoshino, K., and Ogura, A. (2015). Dendritic spine dynamics leading to spine elimination after repeated inductions of LTD. Sci. Rep. 5:7707. doi: 10.1038/srep07707

Hebert, S. S., and De Strooper, B. (2009). Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 32, 199–206. doi: 10.1016/j.tins.2008.12.003

Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., et al. (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831–843. doi: 10.1016/j.neuron.2006.10.035

Hu, Z., Yu, D., Gu, Q. H., Yang, Y., Tu, K., Zhu, J., et al. (2014). miR-191 and miR-135 are required for long-lasting spine remodelling associated with synaptic long-term depression. Nat. Commun. 5:3263. doi: 10.1038/ncomms4263

Ittner, L. M., Ke, Y. D., Deleuver, F., Bi, M., Gladbach, A., van Eersel, J., et al. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142, 387–397. doi: 10.1016/j.cell.2010.06.036

Jasinska, M., Milek, J., Cymerman, I. A., Leski, S., Kaczmarek, L., and Dziembowska, M. (2016). miR-132 regulates dendritic spine structure by direct targeting of matrix metalloproteinase 9 mRNA. Mol. Neurobiol. 53, 4701–4712. doi: 10.1007/s12035-015-3938-z

DATA AVAILABILITY STATEMENT

All datasets generated and analyzed for this study are included in the article/supplementary material.

AUTHOR CONTRIBUTIONS

ER-Z, MH-S, BM, UG-P, VS-G, AM-A, and AC-A equally contributed to the literature research, writing, and correcting of this perspective.

FUNDING

The present work was supported by CONACYT scholarship #593038.
Ju, J., and Zhou, Q. (2018). Dendritic Spine Modifications in Brain Physiology. Neuroplasticity - Insights of Neural Reorganization, Victor V. Chaban, IntechOpen. Available at: https://www.intechopen.com/books/neuroplasticity-insights-of-neural-reorganization/dendritic-spine-modifications-in-brain-physiology (accessed September 18, 2019).

Korkottan, E., and Segal, M. (1999). Release of calcium from stores alters the morphology of dendritic spines in cultured hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 96, 12068–12072. doi: 10.1073/pnas.96.21.12068

Lee, K., Kim, J. H., Kwon, O. B., An, K., Ryu, J., Cho, K., et al. (2012). An activity-regulated microRNA, mir-188, controls dendritic spine plasticity and synaptic downregulation by downregulating neuropilin-2. J. Neurosci. 32, 5678–5687. doi: 10.1523/JNEUROSCI.6471-11.2012

Lee, S. T., Chu, K., Jung, K. H., Kim, J. H., Huh, J. Y., Yoon, H., et al. (2012). miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann. Neurol. 72, 269–277. doi: 10.1002/ana.23588

Li, F., Wei, G., Bai, Y., Li, Y., Huang, F., Lin, J., et al. (2015). MicroRNA-574 regulates brain-derived neurotrophic factor in Alzheimer disease model. J. Neurosci. 35, 1156–1165. doi: 10.1523/JNEUROSCI.1547-14.2015

Lippi, G., Steinert, J. R., Marczylo, E. L., D’Oro, S., Fiore, R., Forsythe, I. D., et al. (2011). Regulation of neuritin. Mol. Psychiatry 16, 5701–5714. doi: 10.1038/mp.2009.013

Saneyoshi, T., Fortin, D. A., and Soderling, T. R. (2010). Regulation of spine and synapse formation by activity-dependent intracellular signaling pathways. Curr. Opin. Neurobiol. 20, 108–115. doi: 10.1016/j.conb.2009.09.013

Sarkar, S., Engler-Chiurazzi, E. B., Cavendish, J. Z., Povroznik, J. M., Russell, A. E., Quintana, D. D., et al. (2019). Over-expression of mir-34a induces rapid cognitive impairment and Alzheimer’s disease-like pathology. Brain Res. 1721, 146327. doi: 10.1016/j.brainsci.2019.146327

Scheid, S. W., Price, D. A., Schmitt, F. A., DeKosky, S. T., and Mufson, E. J. (2007). Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501–1508. doi: 10.1212/01.wnl.000026098.46517.8f

Schmitt, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., and Sabatini, B. L. (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2886–2875. doi: 10.1523/JNEUROSCI.4970-06.2007

Segel, M. (1995). Imaging of calcium variations in living dendritic spines of cultured rat hippocampal neurons. J. Physiol. 486(Pt 2), 283–295. doi: 10.113/j.physiol.1995.sp020811

Segel, M. (2017). Dendritic spines: morphological building blocks of memory. Neurobiol. Learn. Mem. 138, 3–9. doi: 10.1016/j.nlm.2016.06.007

Segel, M., and Andersen, P. (2000). Dendritic spines shaped by synaptic activity. Curr. Opin. Neurobiol. 10, 582–586. doi: 10.1016/S0959-4388(00)00123-9

Segel, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106–113. doi: 10.1016/j.bbr.2008.02.016

Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., and Sabatini, B. L. (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2886–2875. doi: 10.1523/JNEUROSCI.4970-06.2007

Siegel, G., Obrist, G., Fiore, R., Oehmen, M., Bicker, S., Christensen, M., et al. (2009). A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat. Cell Biol. 11, 705–716. doi: 10.1038/ncb1876

Song, Y., Hu, M., Zhang, J., Teng, Z. Q., and Chen, C. (2019). A novel mechanism of synaptic and cognitive impairments mediated via microRNA-30b in Alzheimer’s disease. eBioMed. 39, 409–421. doi: 10.1016/j.ebiom.2018.11.059

Spires-Jones, T. L., Meyer-Luehmann, M., Osetek, J. D., Jones, B. P., Stern, E. A., Backsai, B. J., et al. (2007). Impaired spine stability underlies plaque-related spine loss in an Alzheimer’s disease mouse model. Am. J. Pathol. 171, 1304–1311. doi: 10.2353/ajpath.2007.070055

Sklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., et al. (2017). The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45, D362–D368. doi: 10.1093/nar/gkw937

Tada, T., and Sheng, M. (2006). Molecular mechanisms of dendritic spine morphogenesis. Curr. Opin. Neurobiol. 16, 95–101. doi: 10.1016/j.conb.2005.1.2001

Torres-Berrio, A., Novel, D., Cuesta, S., Parise, E. M., Restrepo-Lozano, J. M., Larochelle, P., et al. (2019). MiR-218: a molecular switch and potential biomarker of susceptibility to stress. Mol. Psychiatry. doi: 10.1038/s41380-019-0421-425

Tracy, T. E., and Gan, L. (2018). Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease. Curr. Opin. Neurobiol. 51, 134–138. doi: 10.1016/j.conb.2018.04.027

van Deijzer, M. P., Jansen, I. E., Verboven, A. H., Andreassen, O. A., and van de Weijer, M. P. (2006). Natural oligomers of the Alzheimer amyloid beta protein induce reversible synapse loss through down-regulating p250GAP. Proc. Natl. Acad. Sci. U.S.A. 103, 9093–9098. doi: 10.1073/pnas.0803072105

Wei, Z., Meng, X., El Fatimy, R., Sun, B., Mai, D., Zhang, J., et al. (2017). Environmental enrichment prevents Abeta oligomer-induced synaptic dysfunction through mirna-132 and hdac3 signaling pathways. Neurobiol. Dis. 104, 104617. doi: 10.1016/j.nbd.2019.104617

Ye, Y., Xu, H., Su, X., and He, X. (2016). Role of MicroRNA in governing synaptic plasticity. Neural Plast. 2016:4959523. doi: 10.1155/2016/4959523
Zempel, H., and Mandelkow, E. M. (2012). Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener. Dis. 10, 64–72. doi: 10.1159/000332816

Zhang, Y., Guo, H., Kwan, H., Wang, J. W., Kosek, J., and Lu, B. (2007). PAR-1 kinase phosphorylates Dlg and regulates its postsynaptic targeting at the Drosophila neuromuscular junction. Neuron 53, 201–215. doi: 10.1016/j.neuron.2006.12.016

Zhou, C. N., Chao, F. L., Zhang, Y., Jiang, L., Zhang, L., Fan, J. H., et al. (2019). Fluoxetine delays the cognitive function decline and synaptic changes in a transgenic mouse model of early Alzheimer’s disease. J. Comp. Neurol. 527, 1378–1387. doi: 10.1002/cne.24616

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Reza-Zaldivar, Hernández-Sápiens, Minjarez, Gómez-Pinedo, Sánchez-González, Márquez-Aguirre and Canales-Aguirre. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.